Overview

Detailed Summary

Sakar Healthcare Limited is an India‑based integrated pharmaceutical manufacturer and CDMO offering API‑to‑FDF capabilities across oral solids, sterile injectables (liquids and lyophilised), oral liquids and oncology formulations, operating EU‑GMP and WHO‑GMP certified facilities and supplying global partners and own‑brand exports to 60+ countries.
Sakar has deliberately repositioned toward oncology as a value driver: the Bavla facility is EU‑GMP approved, vertically integrates API and finished dosage manufacturing, and currently lists 55 oncology molecules developed with 32 dossiers ready for launch and eleven marketing authorisations granted, signalling a step‑change in product complexity and margin profile.
Q3FY26 displayed a sharp operational inflection: consolidated revenue rose 62% YoY to INR 70.34 crore, EBITDA grew 58% to INR 18.59 crore with 26% margins, and PAT more than doubled to INR 10.25 crore, reflecting improved mix, higher own‑brand exports and early commercialisation of oncology dossiers contributing to near‑term profitability expansion.
Commercial traction is supported by deep industry partnerships and technology transfers: Sakar disclosed inclusion as a manufacturing source for Accord/Intas Imatinib supplies, ten tech‑transfer products in process, longstanding client relationships with major Indian multinationals and a shift to own‑brand exports now contributing roughly 70% of revenues, improving margin resilience.
Sakar emphasizes sustainable process technology and backward integration: investments in flow chemistry, green chemistry principles, CEP/DMF development and API capacity aim to reduce sourcing risk and improve gross margins, while management expects maintenance capex only going forward after significant FY26 capex spend that completed oncology readiness.

Sector: Pharmaceuticals & Biotechnology
Industry: Pharmaceuticals
Market Cap: 1,867 Cr
Volatility: Low Risk
P/E Ratio: 61.2
Industry P/E: 34.1
PEG Ratio: 12.6
P/B Ratio: 5.6
52W High: 871.30
52W Low: 306.35

Sales CAGR

1Y: 15.80%
3Y: 11.47%
5Y: 16.44%
10Y: 17.62%

Profit CAGR

1Y: 49.96%
3Y: 4.72%
5Y: 12.71%
10Y: 25.80%

ROE

TTM: 9.40%
3Y: 5.81%
5Y: 7.16%
10Y: 7.76%

ROCE

TTM: 12.54%
3Y: 7.92%
5Y: 8.58%
10Y: 9.65%

Technicals

‌

Forecasts

Peers

Healthcare Healthcare Pharmaceuticals

Symbol	Watchlist	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
INDOCO		205.40	1,897 Cr	-19.94	2.02	0.10	-10.13	0.77	-3.81
SAKAR		813.60	1,810 Cr	59.39	5.58	0.00	9.40	12.54	6.34
NGLFINE		2819.10	1,740 Cr	36.22	5.29	0.00	14.62	15.37	8.81
WINDLAS		834.95	1,725 Cr	25.96	2.97	0.77	11.44	14.90	7.32
HESTERBIO		1927.30	1,664 Cr	29.90	4.62	0.56	15.45	14.34	8.48
AMRUTANJAN		562.90	1,627 Cr	28.09	4.39	0.00	17.42	23.31	11.38
BETA		1522.90	1,544 Cr	37.21	6.31	0.00	16.95	17.46	8.37
Median: 7 Co.	—	834.95	1,725 Cr	29.90	4.62	0.00	14.62	14.90	8.37

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

Ask AI

Consolidated Quarterly Results (in ₹ Crores)

View Standalone

Total Figures

QoQ Changes

Total Figures

	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Sales	37	43	41	43	43	50	53	58	70	71
Expenses	28	32	30	31	32	35	40	46	52	45
Operating Profit	9.01	11	11	12	12	16	13	11	19	26
OPM %	24.20	25.48	26.00	26.88	27.08	31.31	24.10	19.72	26.43	36.91
Other Income	0.23	0.77	0.46	0.37	0.25	0.18	0.39	1.21	0.51	0.17
Interest	1.79	2.08	1.40	1.64	1.30	4.19	2.14	1.53	1.78	2.41
Depreciation	4.44	4.87	5.06	5.12	5.23	5.48	5.57	5.68	6.37	5.94
Profit Before Tax	3.00	4.80	4.70	5.11	5.48	6.24	5.38	5.36	11	18
Tax %	31.00	34.79	48.72	6.07	17.15	7.69	13.20	15.30	6.39	38.98
Net Profit	2.07	3.12	2.41	4.80	4.53	5.76	4.67	4.54	10	11
EPS in Rs	0.96	1.43	1.07	2.11	2.05	2.62	2.11	2.03	4.59	4.96

Consolidated Profit Loss (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	83	95	128	133	153	178	189
Expenses	63	72	99	100	115	128	137
Operating Profit	20	23	29	33	38	50	52
OPM %	23.55	23.85	22.87	24.85	25.02	27.98	27.33
Other Income	2.02	1.18	2.17	4.67	3.18	1.26	1.19
Interest	2.25	2.48	2.90	5.95	7.59	8.54	9.27
Depreciation	7.08	8.06	9.67	15	18	21	21
Profit Before Tax	12	13	19	17	16	22	22
Tax %	21.30	19.27	19.82	24.40	26.60	18.70	11.03
Net Profit	9.62	11	15	13	12	18	20
EPS in Rs	—	4.83	6.72	5.67	5.25	7.85	13.69
Dividend Payout %	0.00	0.00	0.00	0.00	0.00	0.00	—

Consolidated Balance Sheet (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	15	16	17	19	22	22
Reserves	66	83	110	154	241	264
Borrowings	15	40	90	111	69	75
Other Liabilities	19	39	51	52	57	55
Total Liabilities	115	178	268	336	389	415
Fixed Assets	66	69	205	267	314	309
CWIP	13	49	1.23	6.45	0.32	17
Investments	0.00	0.00	7.11	3.43	0.00	0.00
Other Assets	36	60	55	60	74	90
Total Assets	115	178	268	336	389	415

Consolidated Cash Flows (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	19	15	36	33	24	34
Cash from Investing Activity	-22	-47	-90	-74	-52	-31
Cash from Financing Activity	3.48	32	55	41	27	-3.48
Net Cash Flow	-0.06	-0.22	-0.05	0.06	0.37	-0.16

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Promoters	60.72%	54.15%	53.15%	53.15%	53.15%	53.15%	53.58%	53.58%	52.86%	52.86%	52.86%	52.86%
FIIs	15.74%	14.03%	13.76%	13.52%	13.52%	13.42%	13.58%	13.61%	13.41%	13.31%	13.05%	12.94%
DIIs	0.00%	10.82%	10.62%	10.62%	10.62%	10.62%	10.88%	10.97%	11.25%	11.43%	11.36%	11.32%
Public	23.54%	21.00%	22.47%	22.71%	22.71%	22.80%	21.96%	21.85%	22.48%	22.41%	22.73%	22.87%
Total Shareholders	6,056	7,299	7,001	7,386	7,313	7,867	8,598	8,608	8,115	7,565	7,069	9,580

Market Transactions

Unlock more with professional

Real-time bulk & block deal transactions
Export transaction data for analysis

Projection

Documents

Presentations

Concalls

Reports

Presentations

Investor Presentation

Q4 FY26

Investor Presentation

Q3 FY26

Investor Presentation

Q2 FY26

Available on Pro Plan

Unlock reports, presentations, and AI-powered insights.

Investor Presentation

Q2 FY23

Available on Pro Plan

Unlock reports, presentations, and AI-powered insights.

Actions

Action Type

‌
‌

Announcements

Last 7 days

Newest

Sentiment

Sorry, no results found!

AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.